<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101129617</journal-id>
<journal-id journal-id-type="pubmed-jr-id">30409</journal-id>
<journal-id journal-id-type="nlm-ta">Genes Brain Behav</journal-id>
<journal-id journal-id-type="iso-abbrev">Genes Brain Behav.</journal-id>
<journal-title-group>
<journal-title>Genes, brain, and behavior</journal-title>
</journal-title-group>
<issn pub-type="ppub">1601-1848</issn>
<issn pub-type="epub">1601-183X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31119847</article-id>
<article-id pub-id-type="pmc">7074845</article-id>
<article-id pub-id-type="doi">10.1111/gbb.12583</article-id>
<article-id pub-id-type="manuscript">NIHMS1572699</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Novel Biomarkers to Assess In-Utero Effects of Maternal Opioid Use: First Steps towards Understanding Short and Long Term Neurodevelopmental Sequelae</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Goetzl</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thompson-Felix</surname>
<given-names>Tara</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Darbinian</surname>
<given-names>Nune</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Merabova</surname>
<given-names>Nana</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Merali</surname>
<given-names>Salim</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Merali</surname>
<given-names>Carmen</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sanserino</surname>
<given-names>Kathryne</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tatevosian</surname>
<given-names>Tamara</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fant</surname>
<given-names>Bruno</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wimmer</surname>
<given-names>Mathieu E</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1.</label>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Sciences Center, Houston, TX 77030</aff>
<aff id="A2"><label>2.</label>Department of Psychiatry and Behavioral Science, Temple University Lewis Katz School of Medicine, Philadelphia PA, 19140</aff>
<aff id="A3"><label>3.</label>Shriners Pediatric Research Center, Center for Neural Repair and Rehabilitation, Temple University, Philadelphia, Pennsylvania 19140</aff>
<aff id="A4"><label>4.</label>Temple University School of Pharmacy, Philadelphia, PA 19140</aff>
<aff id="A5"><label>5.</label>Department of Obstetrics &amp; Gynecology, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140</aff>
<aff id="A6"><label>6.</label>Department of Psychiatry, Center for Neurobiology and Behavior, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA, 19104</aff>
<aff id="A7"><label>7.</label>Department of Psychology, Temple University, Philadelphia, PA 19122</aff>
<author-notes>
<fn fn-type="con" id="FN1">
<p id="P1">All authors contributed to the conception, execution and analysis of the experiments and data described in this manuscript. The manuscript was written by Laura Goetzl and edited and approved by the other authors.</p>
</fn>
<corresp id="CR1"><label>*</label>Corresponding Author: <email>laura.goetzl@uth.tmc.edu</email>, 832-835-4066, Department of Ob/Gyn, University of Texas Houston Health Sciences, 6431 Fannin, MSB 3.286, Houston,Texas, 77030</corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P25">Laura Goetzl has submitted a full patent for techniques to isolate FCEs. No other author has a conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2020</year>
</pub-date>
<volume>18</volume>
<issue>6</issue>
<fpage>e12583</fpage>
<lpage>e12583</lpage>
<!--elocation-id from pubmed: 10.1111/gbb.12583-->
<abstract id="ABS1">
<p id="P2">Maternal opioid use disorder is common, resulting in significant neonatal morbidity and cost. Currently, it is not possible to predict which opioid-exposed newborns will require pharmacotherapy for neonatal abstinence syndrome. Further, little is known regarding the effects of maternal opioid use disorder on the developing human brain. We hypothesized that novel methodologies utilizing fetal central nervous system-derived extracellular vesicles isolated from maternal blood can address these gaps in knowledge. Plasma from opioid users and controls between 9 and 21 weeks was precipitated and extracellular vesicles were isolated. Mu opioid and cannabinoid receptor levels were quantified. Label free proteomics studies and unbiased small RNA next generation sequencing was performed in paired fetal brain tissue. Maternal opioid use disorder increased mu opioid receptor protein levels in extracellular vesicles independent of opioid equivalent dose. Moreover, cannabinoid receptor levels in extracellular vesicles were upregulated with opioid exposure indicating cross talk with endocannabinoids. Maternal opioid use disorder was associated with significant changes in extracellular vesicle protein cargo and fetal brain micro RNA expression, especially in male fetuses. Many of the altered cargo molecules and micro RNAs identified are associated with adverse clinical neurodevelopmental outcomes. Our data suggest that assays relying on extracellular vesicles isolated from maternal blood extracellular vesicles may provide information regarding fetal response to opioids in the setting of maternal opioid use disorder. Prospective clinical studies are needed to evaluate the association between extracellular vesicle biomarkers, risk of neonatal abstinence syndrome, and neurodevelopmental outcomes.</p>
</abstract>
<kwd-group>
<kwd>extracellular vesicles</kwd>
<kwd>maternal opioid use disorder</kwd>
<kwd>fetal</kwd>
<kwd>micro RNA</kwd>
<kwd>cannabinoid</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>